JP2018536393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536393A5 JP2018536393A5 JP2018518451A JP2018518451A JP2018536393A5 JP 2018536393 A5 JP2018536393 A5 JP 2018536393A5 JP 2018518451 A JP2018518451 A JP 2018518451A JP 2018518451 A JP2018518451 A JP 2018518451A JP 2018536393 A5 JP2018536393 A5 JP 2018536393A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- antibody
- fragment
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 15
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239438P | 2015-10-09 | 2015-10-09 | |
| GB1517913.8 | 2015-10-09 | ||
| GBGB1517913.8A GB201517913D0 (en) | 2015-10-09 | 2015-10-09 | Anti-WT1/HLA-specific antibodies |
| US62/239,438 | 2015-10-09 | ||
| EP15189753.5 | 2015-10-14 | ||
| EP15189753 | 2015-10-14 | ||
| PCT/EP2016/073587 WO2017060201A1 (en) | 2015-10-09 | 2016-10-04 | Anti-wt1/hla-specific antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536393A JP2018536393A (ja) | 2018-12-13 |
| JP2018536393A5 true JP2018536393A5 (enExample) | 2019-11-14 |
| JP6862435B2 JP6862435B2 (ja) | 2021-04-21 |
Family
ID=58487775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018518451A Expired - Fee Related JP6862435B2 (ja) | 2015-10-09 | 2016-10-04 | 抗ｗｔ１／ｈｌａ特異的抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10836829B2 (enExample) |
| EP (1) | EP3359565A1 (enExample) |
| JP (1) | JP6862435B2 (enExample) |
| HK (1) | HK1258444A1 (enExample) |
| MA (1) | MA45004A (enExample) |
| WO (1) | WO2017060201A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP3366704A1 (en) * | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| CA3065402A1 (en) * | 2017-05-31 | 2018-12-06 | Carsgen Therapeutics Co., Ltd. | Compositions and methods of cellular immunotherapy |
| PT3428194T (pt) | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| BR112020011469A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção |
| JP7470640B2 (ja) | 2018-02-09 | 2024-04-18 | イマティクス ユーエス，アイエヌシー． | Ｔ細胞を製造する方法 |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| US20200384028A1 (en) | 2019-06-06 | 2020-12-10 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| JP2024534825A (ja) | 2021-08-24 | 2024-09-26 | イマティクス ユーエス，アイエヌシー． | 条件付きリガンド交換により産生されたペプチドｍｈｃ複合体を使用する免疫細胞の選択 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| EP4408468A4 (en) | 2021-09-28 | 2025-07-02 | Frontaim Biomedicines Inc | MULTIPLE FORMATS OF MOLECULAR COMPLEXES |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| EP4661902A1 (en) * | 2023-02-06 | 2025-12-17 | Memorial Sloan-Kettering Cancer Center | Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2026006495A1 (en) * | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012236068A1 (en) * | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| US20140271644A1 (en) * | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
| ES2742224T3 (es) * | 2013-11-07 | 2020-02-13 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos anti-WT1/HLA |
| EP3066131A1 (en) * | 2013-11-07 | 2016-09-14 | Memorial Sloan-Kettering Cancer Center | Fc-enhanced anti-wt1/hla antibody |
| WO2015130766A1 (en) * | 2014-02-25 | 2015-09-03 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide |
| WO2016174652A1 (en) * | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
-
2016
- 2016-10-04 JP JP2018518451A patent/JP6862435B2/ja not_active Expired - Fee Related
- 2016-10-04 EP EP16782018.2A patent/EP3359565A1/en not_active Ceased
- 2016-10-04 HK HK19100718.0A patent/HK1258444A1/zh unknown
- 2016-10-04 WO PCT/EP2016/073587 patent/WO2017060201A1/en not_active Ceased
- 2016-10-04 MA MA045004A patent/MA45004A/fr unknown
- 2016-10-07 US US15/288,145 patent/US10836829B2/en not_active Expired - Fee Related
-
2020
- 2020-10-13 US US17/069,136 patent/US20210024635A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038003A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2020536488A5 (enExample) | ||
| JP2020500538A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| JP2021500916A5 (enExample) | ||
| JP2011528902A5 (enExample) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| JP2019536806A5 (enExample) | ||
| JP2013542194A5 (enExample) | ||
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2015514110A5 (enExample) | ||
| JP2018521638A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| JP2012116856A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2017525343A5 (enExample) | ||
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| JP2023093753A5 (enExample) | ||
| JP2021517459A5 (enExample) |